An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases
Journal of Interferon & Cytokine Research · 01.04.2024 · 44 (4) · 143-157
DOI: 10.1089/jir.2023.0178 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Interferon & Cytokine Research, erschienen am 01.04.2024. Verfasst von Hale Radi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, Babol University of Medical Sciences, Babol, Iran. Hauptthemen laut MEDLINE: Neoplasms, Autoimmune Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 77 Literaturangaben.
Abstract (Originalsprache)
Interleukin-2 (IL-2) is a cytokine that acts in dual and paradoxical ways in the immunotherapy of cancers and autoimmune diseases. Numerous clinical trial studies have shown that the use of different doses of this cytokine in various autoimmune diseases, transplantations, and cancers has resulted in therapeutic success. However, side effects of varying severity have been observed in patients. In recent years, to prevent these side effects, IL-2 has been engineered to bind more specifically to its receptors on the cell surface, decreasing IL-2 toxicities in patients. In this review article, we focus on some recent clinical trial studies and analyze them to determine the appropriate dose of IL-2 drug with the least toxicities. In addition, we discuss the engineering performed on IL-2, which shows that engineered IL-2 increases the specificity function of IL-2 and decreases its adverse effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
- Biomedical and Microbial Advanced Technologies (BMAT) Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran.
- National Institute for Genetic Engineering and Biotechnology, Tehran University of Medical Sciences, Tehran, Iran.
- Cellular and Molecular Biology Research Center, Babol University of Medical Sciences, Babol, Iran.
ORCID-Profile: Hale Radi
Zitieren
APA
Radi, H., Ferdosi-Shahandashti, E., Kardar, G. A., & Hafezi, N. (2024). An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases. Journal of Interferon & Cytokine Research, 44(4), 143-157. https://doi.org/10.1089/jir.2023.0178
Vancouver
Radi H, Ferdosi-Shahandashti E, Kardar GA, Hafezi N. An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases. Journal of Interferon & Cytokine Research. 2024;44(4):143-157. doi:10.1089/jir.2023.0178
BibTeX
@article{Radi2024,
author = {Radi, Hale and Ferdosi-Shahandashti, Elaheh and Kardar, Gholam Ali and Hafezi, Nasim},
title = {An Updated Review of Interleukin-2 Therapy in Cancer and Autoimmune Diseases},
journal = {Journal of Interferon & Cytokine Research},
year = {2024},
volume = {44},
number = {4},
pages = {143--157},
doi = {10.1089/jir.2023.0178}
}
EUVIMED